CIZ1 B Biomarker

The Science

Transforming Detection with Precision

At Cizzle Bio, Inc., we are dedicated to revolutionizing the early detection of lung cancer through the use of groundbreaking diagnostic tools developed by Cizzle Biotechnology PLC. Central to our scientific approach is the CIZ1B biomarker, a variant of the CIZ1 protein, which plays a critical role in the early detection of lung cancer.

The Challenge of Early Detection

Lung cancer, the leading cause of cancer death worldwide, is notoriously difficult to detect in its early stages. Traditional methods, particularly CT scanning, suffer from high false positive rates—approximately 90%, leading to unnecessary, costly, and invasive follow-ups. This challenge underscores the need for a more precise and less invasive diagnostic method.

Annual Diagnoses

Over 2.2 million individuals are diagnosed with lung cancer each year globally.

0

Mortality and Prevalence

In 2020, cancer claimed 10 million lives worldwide, with lung cancer accounting for nearly 20% of these fatalities - more than any other cancer.

Late-Stage Diagnosis

Approximately 75% of lung cancer cases are diagnosed at a late stage, drastically reducing survival rates and emphasizing the need for early detection.

Survival Rates

The survival rate for lung cancer increases dramatically when diagnosed early. However, less than 20% of cases are caught in these early stages.

Screening Rates

Only 5.8% of the eligible 14.2 million people have been screened for lung cancer as of 2021, pointing to a significant gap in preventive healthcare.

Innovative Diagnostic Solution

Leveraging the pioneering work of Cizzle Biotechnology PLC, we utilize the CIZ1B biomarker to offer a test that significantly reduces the need for invasive testing. This test addresses the clear unmet clinical need for early detection, crucial for enabling curative surgical interventions. Initially designed as an immunoassay for use in hospitals and reference laboratories, there is potential expansion to a point-of-care test suitable for primary healthcare settings.

Advantages of the CIZ1B Biomarker Test

For Patients

  • Less Radiation

    Patients face reduced radiation exposure as the need for repeated CT scans decreases.

  • Non-Invasive

    A simple blood test replaces invasive procedures.

  • Convenient

    There is no need for visits to specialized scanning facilities.

  • Faster Diagnosis

    The test reduces the waiting period for results, accelerating the diagnostic process.

For Healthcare Systems

  • Resource Efficiency

    Reduces the reliance on CT scanners, freeing up these critical resources for other uses.

  • Cost-Effective

    Lowers healthcare costs by eliminating unnecessary invasive procedures.

Scientific Foundations and Clinical Potential

The CIZ1B biomarker forms a stable complex with fibrinogen in the bloodstream, a characteristic that facilitates its detection and quantification. Patented monoclonal antibodies developed by Cizzle Biotechnology PLC detect CIZ1B in blood plasma or lung cancer biopsies with high sensitivity and specificity. Early clinical data supports the use of CIZ1B as a reliable cancer biomarker.

Commercial Strategy and Progress

Through our exclusive licensing agreement with Cizzle Biotechnology PLC, we are positioned to bring these advanced diagnostic tools to the U.S. and Canadian markets. Our collaboration with Bio-Techne aims to refine our immunoassay and adapt it for broader clinical and commercial use, potentially transforming it into a routine screening tool available in doctors' offices and pharmacies.

Our Commitment to Innovation

Cizzle Bio, Inc. is committed to continuing the innovation initiated by Cizzle Biotechnology PLC. By focusing on biomarkers like CIZ1B, we are paving the way for earlier, more accurate diagnoses and better patient outcomes.

Explore More on Our Resources Page

Dive deeper into the fascinating world of biomarker research and stay updated with the latest advancements by visiting our Resources page. Discover comprehensive articles, detailed discussions, and expert insights that further explore the science behind early cancer detection and much more.